Quadrivalent HPV protects against VaIN
The European Medicines Agency has recommended granting a license extension to the quadrivalent human papillomavirus (HPV) vaccine (Gardasil®).
This vaccine is already licensed for the prevention of high grade cervical dysplasia (CIN 2/3), high grade vulval dysplasia (VIN 2/3) and genital warts.
This extension will add prevention of high grade vaginal dysplasia (VaIN 2/3) to the indications for the vaccine. The Department of Health is due to announce which vaccine is to be used for the national HPV programme later this month but it would seem that there are distinct advantages to this vaccine over the bivalent alternative.
Action: Clinicians should be aware of the growing data to support HPV vaccination.
| « Steroids effective for gout | Drug Safety Update, Issue 11 » |
[...] previously noted, Gardasil® has a wider range of licensed indications based on the current Summaries of Product [...]
Pingback by Prescribing Advice for GPs » HPV vaccine announced — June 19, 2008 #